scholarly journals EFFICACY OF SALVAGE CHEMOTHERAPY AFTER IMMUNE CHECKPOINT INHIBITOR IN NON-SMALL CELL LUNG CANCER PATIENTS

Respirology ◽  
2018 ◽  
Vol 23 ◽  
pp. 286-286
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Salvage Chemotherapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e21034-e21034
Author(s):  
Hiromi Watanabe ◽  
Toshio Kubo ◽  
Kiichiro Ninomiya ◽  
Daisuke Minami ◽  
Kenichiro Kudo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Small Cell ◽  
Efficacy And Safety ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals Identification of Biomarkers for Non–small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor

2020 ◽  
Vol 40 (7) ◽  
pp. 3889-3896
Author(s):  
SOUSUKE KUBO ◽  
NOBUAKI KOBAYASHI ◽  
KOHEI SOMEKAWA ◽  
MOMO HIRATA ◽  
CHISATO KAMIMAKI ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals Effectiveness of corticosteroids on immune checkpoint inhibitor-induced interstitial pneumonia among patients with a history of interstitial pneumonia: A case series

2021 ◽  
Vol 9 ◽  
pp. 2050313X2110313
Author(s):  
Takenori Ichimura ◽  
Miwa Hinata ◽  
Daisuke Ichikura ◽  
Shinya Suzuki
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Interstitial Pneumonia ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
History Of

There are few reports on the effectiveness of corticosteroids for immune checkpoint inhibitor-induced interstitial pneumonia in patients with a history of interstitial pneumonia. We report on 10 non-small cell lung cancer patients with a history of interstitial pneumonia who experienced immune checkpoint inhibitor-induced interstitial pneumonia. The immune checkpoint inhibitor-induced interstitial pneumonia lasted for a median duration of 41.5 days (range = 22–127 days). Eight of the ten patients responded to corticosteroid monotherapy; one patient responded to corticosteroids and the immunosuppressant, tacrolimus; and one patient did not improve after corticosteroid treatment. In non-small cell lung cancer patients with a history of interstitial pneumonia, immune checkpoint inhibitor-induced interstitial pneumonia was generally responds to corticosteroids.

Sign in / Sign up

Export Citation Format

Share Document